| Schaverien, Mark V |
University Of Tx Md Anderson Can Ctr
United States |
Lymphedema Prevention Through Immediate Lymphatic Reconstruction |
5R01CA292908-02 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Schedin, Pepper J |
Oregon Health & Science University
United States |
NSAIDs During Postpartum Involution for Breast Cancer Chemoprevention |
5R01CA169175-11 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Schenker, Yael |
University Of Pittsburgh At Pittsburgh
United States |
Patient-centered and efficacious advance care planning in cancer: the PEACe comparative effectiveness trial |
5R01CA235730-06 |
|
Brennan Streck, Ph.D., RN, M.P.H. |
| Schmidt, Christian Maximillian |
Indiana University Indianapolis
United States |
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer |
5U01CA239522-05 |
|
Claire Zhu, Ph.D. |
| Schmit, Stephanie L. |
Cleveland Clinic Lerner Com-Cwru
United States |
Variation in tumor-associated immune profiles and colorectal cancer outcomes |
5R01CA248931-05 |
|
Asad Umar, D.V.M., Ph.D. |
| Schoen, Robert E. |
University Of Pittsburgh At Pittsburgh
United States |
Blood-Based Testing for Advanced Adenoma |
5U01CA271884-04 |
|
Matthew Young, Ph.D. |
| Schroeck, Florian R |
Veterans Education/Res/Assn/North/Ne
United States |
Replacing Invasive Cystoscopy with Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance |
5R37CA275916-03 |
|
Claire Zhu, Ph.D. |
| Schuetze, Scott Michael |
University Of Michigan At Ann Arbor
United States |
Early Phase Clinical Cancer Prevention Consortium |
2UG1CA242632-06 |
|
Donald Johnsey |
| Sears, Rosalie C |
Oregon Health & Science University
United States |
An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals |
4U01CA294548-02 |
|
Indu Kohaar, Ph.D., M.Phil., M.Sc. |
| Sears, Rosalie C |
Oregon Health & Science University
United States |
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs |
5U01CA278923-03 |
PAR-21-334 (U01 Clinical Trial Optional) |
Matthew Young, Ph.D. |
